ALEXIS Biochemicals: Verruculogen

Advanced Search

You are here: Product Lines > Cell Cycle > Cell Cycle Blockers & Inhibitors / Related Products

ALX-380-210

Revised 08-Apr-08

7-Oxostaurosporine
SYNONYMS	Antibiotic BMY 41950 Antibiotic RK 1409 LCM76-L
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Protein Kinase Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-210-M001		1 mg	330.00 USD

Product Specification

FORMULA:	C₂₈H₂₄N₄O₄
MW:	480.5
CAS NUMBER:	141196-69-2
SOURCE/HOST:	Isolated from Streptomyces sp. MST-AS5345.
PURITY:	≥98% (HPLC)
APPEARANCE:	Yellow solid.
SOLUBILITY:	Soluble in DMSO, dimethyl formamide, methanol or 100% ethanol; slightly soluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C

Product Description

Antibiotic. Potent inhibitor of protein kinase C (PKC). Inhibits the cell cycle at the G2 stage.

Product Specific Literature References

A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). I. Taxonomy and biological activity: H. Osada, et al.; J. Antibiot. 45, 189 (1992) Abstract
A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). II. Fermentation, isolation, physico-chemical properties and structure: H. Koshino, et al.; J. Antibiot. 45, 195 (1992) Abstract

Further Categories Containing This Product:

PKC Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • Staurosporine / Related Products • Antibiotics for Cell Cycle Research • Alkaloids

ALX-340-047

Revised 08-Jul-08

Prostaglandin A2
SYNONYMS	Medullin Prosta-5,10,13-trien-1-oic acid, 15-hydroxy-9-oxo-, (5Z,13E,15S)-
PRODUCT LINE	Inflammation
PRODUCT CATEGORY	Prostaglandins & Prostaglandin Analogs

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-340-047-M001		1 mg	33.00 USD
ALX-340-047-M005		5 mg	147.00 USD

Product Specification

FORMULA:	C₂₀H₃₀O₄
MW:	334.5
CAS NUMBER:	13345-50-1
PURITY:	≥98%
FORMULATION:	Liquid. Solution in methyl acetate.
SOLUBILITY:	Soluble in 100% ethanol (100mg/ml), DMSO (50mg/ml) or dimethyl formamide (75mg/ml); slightly soluble in PBS, pH 7.2 (2.4mg/ml).
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Stable for at least 1 year after receipt when stored at -20°C. PGA₂will be degraded to PGB₂ in basic solutions (pH > 7.4). We do not recommend storing aqueous solutions for more than one day.

Product Description

Blocks cell cycle at the G1 and G2/M phase [1] by inhibiting G1 phase cyclin dependent kinases [2] downregulating cyclin D1 [3]. Modulates all three aspects of the glutathione-mediated biotransformation system, i.e. GSH levels, glutathione S-transferase activity and transport of GSH conjugates [4].

Product Specific Literature References

[1] Prostaglandin A2 blocks the activation of G1 phase cyclin-dependent kinase without altering mitogen-activated protein kinase stimulation: M. Hitomi, et al.; J. Biol. Chem. 271, 9376 (1996) Abstract; Full Text
[2] p21Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation: M. Hitomi, et al.; Oncogene 17, 959 (1998) Abstract
[3] Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover: S. Lin, et al.; Mol. Cell. Biol. 20, 7903 (2000) Abstract; Full Text
[4] Interactions of prostaglandin A2 with the glutathione-mediated biotransformation system: M.L. van Iersel, et al.; Biochem. Pharmacol. 57, 1383 (1999) Abstract

General Information

BACKGROUND/TECHNICAL INFORMATION

To change the solvent, evaporate the methyl acetate under a gentle stream of nitrogen and immediately add the solvent of choice.

Further Categories Containing This Product:

Cell Cycle Blockers & Inhibitors / Related Products

ALX-385-001

Revised 08-Apr-08

Quercetin . dihydrate
SYNONYMS	3,3',4',5,7-Pentahydroxyflavone . 2H₂O
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Flavonoids / Related Products

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-385-001-G005		5 g	15.00 USD
ALX-385-001-G025		25 g	45.00 USD

Product Specification

FORMULA:	C₁₅H₁₀O₇ . 2H₂O
MW:	302.2 . 36.0
CAS NUMBER:	6151-25-3
MERCK INDEX:	14: 8034
RTECS:	LK8950000
SOURCE/HOST:	Isolated from Sophora japonica L.
PURITY:	≥95% (HPLC)
APPEARANCE:	Yellow powder with a green or brown cast.
SOLUBILITY:	Soluble in 100% ethanol or 1M sodium hydroxide; almost insoluble in water.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	+20°C
HAZARD:	MAY BE MUTAGENIC. TOXIC.

Product Description

Antioxidant flavonoid. Inhibitor of mitochondrial ATPase, cAMP- and cGMP-phosphodiesterases. Inhibitor of protein tyrosine kinases and protein kinase C (PKC). Induces apoptosis. Blocks cells at the G0/G1 interface. Activator of human deacetylase SIRT1. Reversible inhibitor of fatty acid synthase (FAS). Inhibits the production of the inflammatory mediators nitric oxide (NO), TNF-α and IL-12 in activated macrophages.

Product Specific Literature References

Effects of quercetin and F1 inhibitor on mitochondrial ATPase and energy-linked reactions in submitochondrial particles: D.R. Lang & E. Racker; Biochim. Biophys. Acta 333, 180 (1974)
Flavonoid compounds are potent inhibitors of cyclic AMP phosphodiesterase: A. Beretz, et al.; Experientia 34, 1054 (1978) Abstract
Flavonoids are selective cyclic GMP phosphodiesterase inhibitors: M. Ruckstuhl, et al.; Biochem. Pharmacol. 28, 535 (1979) Abstract
The effect of quercetin on the phosphorylation activity of the Rous sarcoma virus transforming gene product in vitro and in vivo: Y. Graziani, et al.; Eur. J. Biochem. 135, 583 (1983) Abstract
Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin: M. Gschwendt, et al.; BBRC 117, 444 (1983) Abstract
Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin: J. Levy, et al.; BBRC 123, 1227 (1984) Abstract
The phospholipid- and calcium-dependent protein kinase as a target in tumor chemotherapy: H. Grunicke, et al.; Adv. Enzyme Regul. 28, 201 (1989) Abstract
Induction of apoptosis by quercetin: involvement of heat shock protein: Y.Q. Wei, et al.; Cancer Res. 54, 4952 (1994) Abstract
Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction: C.M. Filipeanu, et al.; Eur. J. Pharmacol. 281, 29 (1995) Abstract
Structure-antioxidant activity relationships of flavonoids and phenolic acids: C.A. Rice-Evans, et al.; Free Radical Biol. & Med. 20, 933 (1996), (Review) Abstract
Molecular mechanisms in the antiproliferative action of quercetin: B. Csokay, et al.; Life Sci. 60, 2157 (1997) Abstract
Modulation of the heat-induced activation of mitogen-activated protein (MAP) kinase by quercetin: Y. Nagasaka & K. Nakamura; Biochem. Pharmacol. 56, 1151 (1998) Abstract
Quercetin-induced apoptosis in colorectal tumor cells: possible role of EGF receptor signaling: M. Richter, et al.; Nutr. Cancer 34, 88 (1999) Abstract
Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line: M. Russo, et al.; FEBS Lett. 462, 322 (1999) Abstract
The effect of quercetin on induction of apoptosis: J. Rzymowska, et al.; Folia Histochem. Cytobiol. 37, 125 (1999) Abstract
Quercetin, coenzyme Q10, and L-canavanine as protective agents against lipid peroxidation and nitric oxide generation in endotoxin-induced shock in rat brain: H.M. Abd El-Gawad & A.E. Khalifa; Pharmacol. Res. 43, 257 (2001) Abstract
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan: K.T. Howitz, et al.; Nature 425, 191 (2003)
Presence of fatty acid synthase inhibitors in the rhizome of Alpinia officinarum hance: B.H. Li and W.X. Tian; J. Enzyme Inhib. Med. Chem. 18, 349 (2003) Abstract
Inhibitory effects of the flavonoids isolated from Waltheria indica on the production of NO, TNF-alpha and IL-12 in activated macrophages: Y.K. Rao, et al.; Biol. Pharm. Bull. 28, 912 (2005) Abstract
Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?: R. Lupu & J. A. Menendez; Curr. Pharm. Biotechnol. 7, 483 (2006), (Review) Abstract
Onions: a source of unique dietary flavonoids: R. Slimestad, et al.; J. Agric. Food Chem. 55, 10067 (2007) Abstract

Further Categories Containing This Product:

PKC Inhibitors • Active Substances from Fruit and Vegetables • Natural Products - ATPase Inhibitors • Phosphodiesterases / Related Products • Tyrosine Kinase Inhibitors • Fatty Acid Synthase [FAS] / Related Products • Cell Cycle Blockers & Inhibitors / Related Products • Natural Products - Nitric Oxide Pathway Modulators • Natural Products - Apoptosis Inducers & Inhibitors • Natural Products - Antioxidants • Natural Products - Anti-inflammatory Agents • Natural Products - Anti-inflammatory Agents

ALX-380-092

Revised 03-Jul-08

Radicicol
SYNONYMS	Monorden 1aS-(1aR,2Z,4E,14,15aR*)]-8-Chloro-1a,14,15,15a-tetrahydro-9,11-dihydroxy-14-methyl-6H-oxireno[e][2]benzoxacyclotetradecin-6,12(7H)-dione
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics - Antifungal

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-092-M001		1 mg	75.00 USD
ALX-380-092-M005		5 mg	295.00 USD

Product Specification

FORMULA:	C₁₈H₁₇ClO₆
MW:	364.8
CAS NUMBER:	12772-57-5
MERCK INDEX:	14: 6253
RTECS:	RR1105000
SOURCE/HOST:	Isolated from Humicola fuscoatra.
PURITY:	≥98% (HPLC)
APPEARANCE:	White to light yellow powder.
SOLUBILITY:	Soluble in DMSO, methanol or acetone.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
HANDLING:	Protect from light.
HAZARD:	MAY BE CARCINOGENIC. HARMFUL.

Product Description

Antifungal macrocyclic lactone antibiotic with antimalarial activity. Potent inhibitor of HSP90. Binds more strongly to HSP90 (nanomolar affinity) than to Grp94. Also binds to yeast HSP90, E. coli HtpG and TRAP-1. Non-competitive inhibitor of ATP citrate lyase. Anti-angiogenic. Specifically inhibits the interaction between HIF-1α/Arnt heterodimer and the hypoxia-responsive element (HRE), reducing VEGF expression. Protein tyrosine kinase inhibitor, e.g. p60^v-src(IC₅₀=0.27nM). Inhibitor of cyclooxygenase-2 (COX-2) expression (IC₅₀=27nM) without affecting COX-1 expression in LPS-stimulated macrophages. Induces the differentiation of HL-60 cells into macrophages, blocking cell cycle at G1 and G2. Suppressor of NIH 3T3 cell transformation by diverse oncogenes such as mos, ras and src in part by blocking the key signal transduction intermediates such as MAP kinase and GAP-associated p62. Inhibitor of AP-1-, NF-κB- and serum response factor (SRF)-mediated transcription (e.g. expression of iNOS). Represses the transcriptional function of the estrogen receptor. Inhibits archeal growth and DNA topoisomerase VI (a Topo IIB family topoisomerase). Blocks replication of negative-strand RNA viruses.

Product Specific Literature References

Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol: H.J. Kwon, et al.; Cancer Res. 52, 6926 (1992) Abstract
Radicicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis: T. Oikawa, et al.; Eur. J. Pharmacol. 241, 221 (1993) Abstract
Radicicol, a protein tyrosine kinase inhibitor, suppresses the expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide and in experimental glomerulonephritis: P. Chanmugam, et al.; J. Biol. Chem. 270, 5418 (1995) Abstract; Full Text
Suppression of RAS and MOS transformation by radicicol: J.F. Zhao, et al.; Oncogene 11, 161 (1995) Abstract
Induction of differentiation of HL-60 cells by the anti-fungal antibiotic, radicicol: Y. Shimada, et al.; J. Antibiot. 48, 824 (1995) Abstract
Radicicol inhibits tyrosine phosphorylation of the mitotic Src substrate Sam68 and retards subsequent exit from mitosis of Src-transformed cells: I. Pillay, et al.; Cell Growth Differ. 7, 1487 (1996) Abstract
Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway: S. Soga, et al.; J. Biol. Chem. 273, 822 (1998) Abstract; Full Text
Antimalarial activity of radicicol, heptelidic acid and other fungal metabolites: Y. Tanaka, et al.; J. Antibiot. 51, 153 (1998) Abstract
Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol: S.V. Sharma, et al.; Oncogene 16, 2369 (1998) Abstract
Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin: S.M. Roe, et al.; J. Med. Chem. 42, 260 (1999) Abstract
T.W. Schulte, et al.; Mol. Endocrinol. 13, 1435 (1999) Abstract; Full Text
Radicicol suppresses expression of inducible nitric-oxide synthase by blocking p38 kinase and nuclear factor-kappaB/Rel in lipopolysaccharide-stimulated macrophages: Y.J. Jeon, et al.; J. Pharmacol. Exp. Ther. 294, 548 (2000) Abstract; Full Text
Radicicol binds and inhibits mammalian ATP citrate lyase: S.W. Ki, et al.; J. Biol. Chem. 275, 39231 (2000) Abstract; Full Text
Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade: P.N. Kim, et al.; Cell Growth Differ. 12, 543 (2001) Abstract; Full Text
Radicicol-sensitive peptide binding to the N-terminal portion of GRP94: S. Vogen, et al.; J. Biol. Chem. 277, 40742 (2002) Abstract; Full Text
Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol: E. Hur, et al.; Mol. Pharmacol. 62, 975 (2002) Abstract; Full Text
Radicicol represses the transcriptional function of the estrogen receptor by suppressing the stabilization of the receptor by heat shock protein 90: M.O. Lee, et al.; Mol. Cell Endocrinol. 188, 47 (2002) Abstract
Development of radicicol analogues: S. Soga, et al.; Curr. Cancer Drug Targets 3, 359 (2003) Abstract
Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor: K. Harashima, et al.; Int. J. Radiat. Biol. 81, 63 (2005) Abstract
Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol: D. Gadelle, et al.; Nucleic Acid Res. 33, 2310 (2005) Abstract
Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site: M.K. Hadden, et al.; Curr. Top. Med. Chem. 6, 1173 (2006), Review Abstract
The topoisomerase II-Hsp90 complex: a new chemotherapeutic target?: C.R. Barker, et al.; Int. J. Cancer 118, 2685 (2006) Abstract
Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol: K.D. Corbett & J.M. Berger; Nucleic Acids Res. 34, 4269 (2006) Abstract
Chemistry and biology of resorcylic acid lactones: N. Winssinger & S. Barluenga; Chem. Commun. (Camb.) 22 (2007) Abstract
Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses: J.H. Connor, et al.; Virology 362, 109 (2007) Abstract

Further Categories Containing This Product:

NF-kB Pathway Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • Tyrosine Kinase Inhibitors • Estrogen & Estrogen Receptors / Related Products • Antibiotics - Nitric Oxide Pathway Modulators • Antitumor Agents (Hormone-related) • Malaria / Related Products • Antibiotics - Antimalarial • Antibiotics - Protein Kinase Inhibitors • Antibiotics - NF-kB Inhibitors • Antibiotics for Angiogenesis Research • Antibiotics for Cell Cycle Research • HSP90 / HtpG / Related Products • Antibiotics - Topoisomerase Inhibitors • RNA Polymerases / Related Products

ALX-270-346

Revised 28-May-08

Ratjadone A (synthetic)
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-270-346-C002		2 µg	150.00 USD

Product Specification

FORMULA:	C₂₈H₄₀O₅
MW:	456.6
CAS NUMBER:	163564-92-9
SOURCE/HOST:	Synthetic.
PURITY:	≥95%
FORMULATION:	Liquid. Solution in methanol.
SOLUBILITY:	Soluble in methanol (20mg/ml) or aqueous buffers (<100µM).
SHIPPING:	SHIPPED ON DRY ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Sensitive to acids and bases. Unstable in acidic buffer systems (pH<6). Stable in substance as oil and in solution in methanol at -20°C.
HANDLING:	Protect from light.
HAZARD:	TOXIC.

Product Description

Represents a new class of natural compounds, which inhibit proliferation in eukaryotes by blocking nuclear export. As potent as leptomycin B (Prod. No. ALX-380-100) and specific for G1/S checkpoint. Cytotoxic secondary metabolite (IC₅₀=50pg/ml in mouse cell line L929) that arrests tumor cells in the G1 phase at remarkably low concentrations (50pg/ml in HeLa cell line KB3.1). Inhibits the binding between the nuclear export signal (NES) of proteins and the chromosome maintenance region protein (CRM1). Anticancer compound. Belongs to the family of orphan ligands which include polyketides like leptomycin B, callystatin A and other related compounds.

Product Specific Literature References

Antibiotics from gliding bacteria, LXIII. Ratjadone: a new antifungal metabolite from Sorangium cellulosum: D. Schummer, et al.; Liebigs Ann. 685 (1995)
Ratjadon: a new antifungal compound from Sorangium cellulosum (myxobacteria) production, physio-chemical and biological properties: J. Gerth, et al.; J. Antibiot. 48, 973 (1995) Abstract
The chemistry and biology of ratjadone: M. Kalesse, et al.; ChemBioChem. 9, 709 (2001) Abstract
The chemistry and biology of the leptomycin family: M. Kalesse & M. Christmann; Synthesis 8, 981 (2002) Abstract
Ratjadone and leptomycin B block CRM1-dependent nuclear export by identical mechanisms: T. Meissner, et al.; FEBS Lett. 576, 27 (2004)
Nuclear targeting of adenovirus type 2 requires CRM1-mediated nuclear export: S. Strunze, et al.; Mol. Biol. Cell 16, 2999 (2005) Abstract

Further Categories Containing This Product:

Cell Cycle Blockers & Inhibitors / Related Products • Nuclear Envelope & Nuclear Transport • Antitumor Antibiotics • Antibiotics - Antifungal • Antitumor Agents (Anti-proliferative)

ALX-270-369

Revised 28-May-08

Ratjadone C (native)
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-270-369-C005		5 µg	180.00 USD

Product Specification

FORMULA:	C₂₈H₄₀O₅
MW:	456.6
SOURCE/HOST:	Isolated from Sorangium cellulosum.
PURITY:	≥95%
FORMULATION:	Liquid. Solution in methanol (5µg in 1ml).
SOLUBILITY:	Soluble in methanol (>50mg/ml). Sparingly soluble in aqueous buffers (up to 10µg/ml in PBS).
SHIPPING:	SHIPPED ON BLUE ICE
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Acid and base sensitive. Unstable in acidic and alkaline buffer systems (pH <6 or >7). Stable in methanolic solution at -20°C.
HANDLING:	Protect from light.
HAZARD:	TOXIC.

Product Description

Cytotoxic secondary metabolite that inhibits cell growth of mammalian cell lines in the picomolar range (IC₅₀=0.2ng/ml with L929 mouse cells) including multidrug resistant (MDR) HeLa cells (IC₅₀=0.1ng/ml with KB-V1). Like leptomycin B (Prod. No. ALX-380-100), ratjadone C binds covalently to the nuclear export protein CRM1. It inhibits cargo protein binding to the leucine-rich nuclear export sequence and thereby blocks nuclear export.

Product Specific Literature References

Antibiotics from gliding bacteria, LXIII. Ratjadone: a new antifungal metabolite from Sorangium cellulosum: D. Schummer, et al.; Liebigs Ann. 685 (1995)
Ratjadon: a new antifungal compound from Sorangium cellulosum (myxobacteria) production, physico-chemical and biological properties: K. Gerth, et al.; J. Antibiot. (Tokyo) 48, 973 (1995) Abstract
The chemistry and biology of the leptomycin family: M. Kalesse & M. Christmann; Synthesis 8, 981 (2002) Abstract
Ratjadones inhibit nuclear export by blocking CRM1/exportin 1: M. Koster, et al.; Exp. Cell. Res. 286, 321 (2003) Abstract

Further Categories Containing This Product:

Cell Cycle Blockers & Inhibitors / Related Products • Nuclear Envelope & Nuclear Transport • Antitumor Antibiotics • Antibiotics - Antifungal • Antitumor Agents (Anti-proliferative)

ALX-380-216

Revised 20-Jun-08

Reveromycin A
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-216-MC01		0.1 mg	150.00 USD
ALX-380-216-MC25		0.25 mg	320.00 USD

Product Specification

SEQUENCE:	134615-37-5
FORMULA:	C₃₆H₅₂O₁₁
MW:	660.8
SOURCE/HOST:	Isolated from Streptomyces sp. MST-AS5344.
PURITY:	≥99% (HPLC)
APPEARANCE:	White to tan solid.
SOLUBILITY:	Soluble in ethyl acetate, 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Unstable in acidic conditions.

Product Description

Antibiotic. Dominant analog of the reveromycin complex. Inhibitor of the mitogenic activity of epidermal growth factor (EGF). G1 phase cell cycle inhibitor, selectively inhibiting isoleucyl-tRNA synthetase. Displays antiproliferative as well as potent antifungal activity. Induces apoptosis in osteoclasts thus inhibiting bone resorption.

Product Specific Literature References

Reveromycins, new inhibitors of eukaryotic cell growth. I. Producing organism, fermentation, isolation and physico-chemical properties: H. Takahashi, et al.; J. Antibiot. (Tokyo) 45, 1409 (1992) Abstract
Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities: H. Takahashi, et al.; J. Antibiot. (Tokyo) 45, 1414 (1992) Abstract
Chemical modification of reveromycin A and its biological activities: T. Shimizu, et al.; Bioorg. Med. Chem. Lett. 12, 3363 (2002) Abstract
Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A: Y. Miyamoto, et al.; J. Biol. Chem. 277, 28810 (2002) Abstract; Full Text
Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity: H. Muguruma, et al.; Clin. Cancer Res. 11, 8822 (2005) Abstract; Full Text
Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts: J.T. Woo, et al.; PNAS 103, 4729 (2006) Abstract; Full Text
Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone: S. Sone and S. Yano; Cancer Metastasis Rev. 26, 685 (2007) Abstract
Regulation of osteoclast polarization: N. Takahashi, et al.; Odontology 95, 1 (2007), (Review) Abstract

Further Categories Containing This Product:

Antibiotics - Apoptosis Inducers & Inhibitors • Cell Cycle Blockers & Inhibitors / Related Products • EGFR Kinase Inhibitors • Antibiotics - Antifungal • Bone Metabolism Other Products

ALX-380-217

Revised 08-Apr-08

Reveromycin B
PRODUCT LINE	Natural Products / Antibiotics
PRODUCT CATEGORY	Antibiotics for Cell Cycle Research

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-380-217-MC25		0.25 mg	320.00 USD

Product Specification

FORMULA:	C₃₆H₅₂O₁₁
MW:	660.8
CAS NUMBER:	144860-68-4
SOURCE/HOST:	Isolated from Streptomyces sp. MST-AS5344.
PURITY:	≥90% (HPLC)
APPEARANCE:	White to tan solid.
SOLUBILITY:	Soluble in ethyl acetate, 100% ethanol, methanol, dimethyl formamide or DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C
USE/STABILITY:	Unstable in acidic conditions.